Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Epidermal growth factor receptor (EGFR) family is implicated in breast cancer, with targeted therapies like trastuzumab showing efficacy.
• Resistance to EGFR-targeted agents may arise from alternative pathway activation, notably the PI3K/Akt/MTOR pathway.
• Investigating combined inhibition strategies is crucial for overcoming treatment resistance.

Purpose of the Study:

• To evaluate the synergistic effects of combining EGFR inhibitors (erlotinib, gefitinib) with PI3K/MTOR pathway inhibitors (ZSTK474, sirolimus).
• To assess these combinations in breast cancer cell lines harboring specific mutations (EGFR, BRAF, AKT, PI3K).

Main Methods:

• Utilized MCF10a isogenic cell lines with defined mutations in EGFR, BRAF, AKT, and PI3K.
• Administered combinations of EGFR inhibitors with PI3K or MTOR inhibitors.
• Assessed cell viability and pathway activity.

Main Results:

• A PI3K mutation significantly increased the sensitivity of MCF10a cells to EGFR inhibitors compared to parental cells and other mutations.
• Combined treatment with EGFR inhibitors and either ZSTK474 (PI3K inhibitor) or sirolimus (MTOR inhibitor) demonstrated enhanced anti-cancer activity.
• The combination therapy proved more effective than single-agent treatments in the studied cell lines.

Conclusions:

• Simultaneous targeting of the PI3K and EGFR pathways presents a promising therapeutic strategy for breast cancer.
• These findings support further investigation into combination therapies involving PI3K/MTOR and EGFR inhibitors.
• The enhanced activity observed in PI3K-mutated cell lines suggests a potential predictive biomarker for treatment response.